HLUYYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Stats
本日の出来高	7 539.00
平均出来高	1 786.00
時価総額	0.00
Last Dividend	$0.204 ( 2022-03-24 )
Next Dividend	$0 ( N/A )
P/E	28.95
ATR14	$2.36 (10.72%)

H. Lundbeck A/S 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

H. Lundbeck A/S 財務諸表

Annual	2021
収益:	$16.30B
総利益:	$12.65B (77.62 %)
EPS:	$0

FY	2021
収益:	$16.30B
総利益:	$12.65B (77.62 %)
EPS:	$0

FY	2020
収益:	$17.67B
総利益:	$13.50B (76.42 %)
EPS:	$7.95

FY	2019
収益:	$17.36B
総利益:	$13.97B (80.50 %)
EPS:	$13.42

Financial Reports:

No articles found.

H. Lundbeck A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

H. Lundbeck A/S Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.350	2013-03-22
Last Dividend	$0.204	2022-03-24
Next Dividend	$0	N/A
Payout Date	2022-04-05
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	$4.94	--
Avg. Dividend % Per Year	0.00%	--
Score	0.28	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-10-14)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.28

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RWCB	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
FIDS	Ex Dividend Junior	2023-05-18	Annually	0.00%
WEGZY	Ex Dividend Knight	2023-09-29	Bi-Monthly	0.00%
MAORF	Ex Dividend Junior	2023-08-17	Sporadic	0.00%
CLZNY	Ex Dividend Knight	2023-06-09	Annually	0.00%
SNMCY	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
HCBC	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
AMFC	Ex Dividend Knight	2023-08-31	Annually	0.00%
NHYDY	Ex Dividend Knight	2023-05-11	Annually	0.00%
CSXXY	Ex Dividend Knight	2023-09-15	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0	1.500	-1.111	-1.667	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.977	0.800	-0.117	-0.0934	[1 - 3]
quickRatioTTM	0.258	0.800	-3.19	-2.55	[0.8 - 2.5]
cashRatioTTM	0.258	1.500	9.68	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	13.14	1.000	6.25	6.25	[3 - 30]
operatingCashFlowPerShareTTM	3.08	2.00	8.97	10.00	[0 - 30]
freeCashFlowPerShareTTM	0	2.00	0	0	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.776	1.000	0.397	0.397	[0.2 - 0.8]
operatingProfitMarginTTM	0.123	1.000	9.53	9.53	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0	1.000	-0.101	0	[1 - 100]
returnOnEquityTTM	0	2.50	-0.714	-1.667	[0.1 - 1.5]
freeCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.08	2.00	8.97	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0375	1.000	-1.561	0	[0.1 - 0.5]
Total Score				0.155

H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.